|
United States Government International Assistance for Children in Adversity Working Group
|
Committee, Work group, Advisory group, or Task Force
|
ACF, CDC, FDA, HRSA, OS
|
NICHD, NIAAA, NIDA, NIMH, OD/DPCPSI/OBSSR, OD/DPCPSI/ORWH
|
United States Government International Assistance for Children in Adversity Working Group seeks to improve the coordination and coherence of the overall United States Government portfolio of assistance for children in adversity. The US Government will help ensure that children under 5 survive and thrive by supporting comprehensive programs that promote the sound development of children through the integration of health, nutrition, and family support. US Government assistance will support and enable families to care for their children; prevent unnecessary family-child separation; and promote appropriate, protective, and permanent family care. The US Government will facilitate the efforts of national governments and partners to prevent, respond to, and protect children from violence, exploitation, abuse, and neglect. The US Government will support partners to build and strengthen holistic and integrated models to promote the best interests of the child. Finally, the US Government will devote resources to building and maintaining a strong evidence base on which future activities to reach and assist the most vulnerable children can be effectively planned and implemented. The US Government will institutionalize and integrate the components of this plan in its diplomatic, development, and humanitarian efforts overseas.
|
|
Update to Health and Human Services National HIV/AIDS Strategy
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, HRSA, IHS, OS, SAMHSA
|
OD/DPCPSI/OAR, NIAID, NIDA, NIMH
|
The National HIV/AIDS Strategy (NHAS) is a five-year plan that details principles, priorities, and actions to guide our collective national response to the HIV epidemic. First released on July 13, 2010, the Strategy identified a set of priorities and strategic action steps tied to measurable outcomes for moving the Nation forward in addressing the domestic HIV epidemic. In 2015 the NHAS was updated to 2020 and reflects the work accomplished and the new scientific developments. Initial discussions have begun to develop the next iteration of the NHAS.
|
|
US Agency for International Development Antiretroviral Optimization Program Advisory Committee (USAID ART Optimization PAC)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA
|
NIAID
|
The goal of the USAID Project Advisory Committee is to guide USAID''s efforts in the area of ART optimization as part of their Cooperative Agreement "Antiretroviral Therapy Simplification – Drug Regimen,” which was awarded to Wits Reproductive Health and HIV Institute with a total estimated ceiling of $50.2 million over five years (October 2015 to October 2020). The Committee has members from the US government, WHO, UNITAID, Paediatric European Network for Treatment of AIDS, Clinton Health Access Initiative, Gates Foundation, Global Fund, university clinical programs, and community representatives. Industry representatives provide background information without sitting on the Project Advisory Committee.
|
|
US Government Inter agency Working Group on Nanotechnology Environmental, and Health Implications (NEHI), of the Nanoscale Science, Engineering, and Technology Subcommittee (NSET) of the National Science and Technology Council (NSTC)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA
|
NCI, NIEHS
|
The Nanoscale Science, Engineering, and Technology (NSET) Subcommittee and Nanotechnology Environmental, and Health Implications (NEHI) Working Group provide leadership in establishing the national nanotechnology environmental, health, and safety research agenda and in communicating data and information related to environmental and health aspects of nanotechnology between National Nanotechnology Initiative (NNI) agencies and with the public. NNI activities support the development of new tools and methods required for the research that will enable risk analysis and assist in regulatory decision-making. NNI agencies engage and interact with regional, state, and local groups, educational institutions, industry-supported groups, and non-governmental organizations to enhance the impact and value of NNI efforts and to provide a collaborative approach.
|
|
US Government Zika Vaccine Development Working Group
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, OS
|
NIAID
|
HHS established the Zika Vaccine Development Working Group, which includes representatives from various US Government agencies (Biomedical Advanced Research and Development Authority (BARDA), Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA)) to coordinate research efforts, mobilization of domestic and international research infrastructure, and partnerships with industry to accelerate the development of a safe and effective Zika vaccine.
|
|
US Pediatric Formulations Initiative (PFI) Taste and Flavor Working Group
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NICHD
|
The PFI is designed to look at all the factors that affect the development of pediatric drugs. The goals are to create a roadmap for removing/mitigating barriers to pediatric drug development, and to connect researchers and experts in pediatric formulation to discuss issues and challenges that may stimulate further research in the field. This working group focuses on research on the sensory aspects of pediatric formulations, including taste, smell, and flavor.
|
|
US Preventive Services Task Force (USPSTF)
|
Resource Development
|
AHRQ
|
OD/DPCPSI/ODP, NCI
|
The US Preventive Services Task Force (USPSTF) is an independent panel of non-Federal experts in prevention and evidence-based medicine. The USPSTF uses information from systematic evidence reviews to make recommendations for a broad range of clinical preventive health care services (such as screening, counseling, and preventive medications) that are delivered in or referred from primary care practice. USPSTF recommendations are developed for primary care clinicians, health systems, and policy-makers, and published in the form of "Recommendation Statements."
The Agency for Healthcare Research and Quality (AHRQ) has been authorized by the US Congress to convene the Task Force and to provide ongoing scientific, administrative, and dissemination support to the Task Force. The NIH Office of Disease Prevention (ODP) works closely with AHRQ and the USPSTF to provide scientific input from NIH Institutes and Centers on draft research plans, draft evidence reviews, and draft recommendation statements. The ODP also disseminates information to NIH Institutes and Centers about high-priority evidence gaps for clinical preventive services that have been identified by the USPSTF.
|
|
US Public Health Service (USPHS) Physicians Professional Advisory Committee (PPAC)
|
Committee, Work group, Advisory group, or Task Force
|
ACF, ACL, AHRQ, ATSDR, BARDA, CDC, CMS, FDA, HRSA, IHS, OS, OSG, SAMHSA
|
NIAID
|
The purpose of this committee is to provide advice and consultation to the Surgeon General on issues relating to the professional practice and personnel activities, civil service, and Commissioned Corps of the Medical Category. The committee provides advisory assistance to the Chief Professional Officer and to the Agency and/or Program Heads of the USPHS and to non-PHS programs that routinely use USPHS personnel.
|
|
USDA-HHS Birth to 24 Months & Pregnant Women Project Federal Expert Group
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA
|
NHLBI, NCI, NICHD, NIDDK, OD/DPCPSI/OBSSR, OD/DPCPSI/ODP
|
The current work includes identifying topics of public health importance and conducting a small number of systematic reviews on diet and health for infants, toddlers, and women who are pregnant; it will not include specific dietary recommendations or advice. The scientific basis for dietary guidance for these population groups will be informed by the advisory report of the next (2020) Dietary Guidelines Advisory Committee.
|
|
Vaccine Research Center- National Vaccine Program Office (NVPO) Collaboration
|
Other
|
CDC, FDA
|
NIAID
|
NVPO provided personnel in a Detail Assignment to support the following activities: 1. Guide and assist with NIAID''s Emerging Infectious Disease (EID) Outbreak Research Reponse; 2. Direct strategic planning and advance development for the VRC''s expanding portfolio of candidate vaccines and biotherapeutics; 3. Lead maternal immunization clinical research and vaccine safety surveying and monitoring for VRC''s EID Outbreak Research Response to the Zika virus epidemic, and other vaccine candidates being developed at the VRC; 4. Facilitate collaborative efforts with stakeholders, NIAID, HHS, Centers for Disease Control and Prevention, Food and Drug Administration, academic institutions, private organizations, and industries dedicated to expanding the state of knowledge of vaccine health globally, to enhance research and clinical readiness; 5. Facilitate advancement of a national strategy to develop medical products and strategies to counter emerging and re-emerging infectious diseases.
|